Teligent, Inc. (Nasdaq: TLGT), ("Teligent" or the "Company"), a New Jersey-based specialty generic pharmaceutical company, today announced it has appointed Carter Pate to its Board of Directors, effective immediately. Mr. Pate will serve on the Audit and Nominating and Corporate Governance Committees.

Teligent, Inc. (Nasdaq: TLGT), ("Teligent" or the "Company"), a New Jersey-based specialty generic pharmaceutical company, today announced it has appointed industry veteran William S. Marth to its Board of Directors, effective immediately. Mr. Marth brings over 25 years of expertise and a proven track record of leading companies in the generic pharmaceutical and contract manufacturing industries.

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 27) Abbott Laboratories (NYSE: ABT) (reacted to fourth-quarter results) Aslan Pharmaceuticals Ltd (NASDAQ: ASLN) Atea Pharmaceuticals Inc (NASDAQ: AVIR) AtriCure Inc. (NASDAQ: ATRC) Aziyo Biologics Inc (NASDAQ: AZYO) Cassava Sciences Inc (NASDAQ: SAVA) Collegium Pharmaceutical Inc (NASDAQ: COLL) Collplant Biotechnologies Ltd – ADR (NASDAQ: CLGN) Corcept T...

Teligent, Inc. (Nasdaq: TLGT), ("Teligent" or the "Company"), a New Jersey-based specialty generic pharmaceutical company, today announced a series of strategic actions in partnership with its senior lenders and its Series C noteholders to recapitalize and enhance the Company's financial flexibility. Through these actions and with support from its senior lenders and Series C noteholders, the Company is strengthening its balance sheet while also working to raise additional capital and position it...

BUENA, N.J., Jan. 22, 2021 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey-based specialty generic pharmaceutical company, previously received notice from The Nasdaq Stock Market (“Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of the Company not having timely filed its Quarterly Report on Form 10-Q for the three months ended September 30, 2020 (the “Form 10-Q”) with the Securities and Exchange...

BUENA, N.J., Dec. 31, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the third quarter ended September 30, 2020.Financial HighlightsThird Quarter 2020 vs. Second Quarter 2020 * Revenues of $14.3 million, an increase of $0.8 million or 6%, on stronger demand for US topical products * Gross profit of $0.1 million, a decrease of $2.4 million driven by additional inventory reserves a...

Scheduled to Reconvene on December 16, 2020 Company Urgently Encourages Stockholders to VoteBUENA, N.J., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (Nasdaq: TLGT), a New Jersey-based specialty generic pharmaceutical company (the “Company”), announced today that its Special Meeting of Stockholders, scheduled for October 22, 2020, adjourned to November 11, 2020 and then to November 25, 2020, was convened and adjourned without any business being conducted due to the fact that a quorum was no...

During Q2, Teligent (NASDAQ: TLGT) brought in sales totaling $13.59 million. However, earnings decreased 75.81%, resulting in a loss of $4.37 million. In Q1, Teligent brought in $7.45 million in sales but lost $18.05 million in earnings.Why ROCE Is Significant Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth ...